Non-hormonal Male Contraceptive Product Development Pipeline
Clinical (Phase II/III)
Vas Occlusives
RISUG
- Injectable polymer that blocks the vas (reversible)
Sujoy Guha
Indian Institute of Technology Kharagpur
Clinical (Phase I)
Sperm-Egg Fusion/
Other
Pre-Clinical
Eppin
- Sperm motility target via binding to EPPIN protein on the surface of human sperm
Mike O'Rand
Eppin Pharma
Reversible Vas Occlusives
Vasalgel
- injectable polymer that blocks vas
(reversible)
Ed Gillis
Revolution Contraceptives
VasDeBlock
- Small device implanted in the vas
(reversible)
Niels Lindgren
VasDeBlock Medical ApS
Echo-VR
- Injectable hydrogel formulation
that blocks vas (reversible)
Kevin Eisenfrats
Contraline
Early Stage/Discovery
Sperm-egg Fusion/
Other
TSSK 6
- Sperm-egg fusion target via
translocation of Izumo
SD1
- Natural product
- Imposes structural
changes in sperm
Wei Yan
University of Nevada, Reno
CD52g
- Sperm epitope being developed as
antibody-based female contraceptive
Deborah Anderson
Boston University
Sperm Transport
Combination alpha-adreno/
purinoreceptor antagonists
- Prevention of sperm transport
and ejaculation
Sabatino Ventura
Monash University
Sperm Motility
USP51
- Sperm motility via
deubiquitinating enzymes
Christopher Payne
Northwestern
Feinberg School of Medicine
SLO3
- Sperm motility target via
potassium channel regulation
and sperm structural changes
Celia Santi
Washington University
in St. Louis
CRISP1
- Sperm motility target via
decapactiation factor
- Potential target for sperm-egg
fusion and sperm motility
Patricia Cuasnicu
IBYME
Na/K ATPase
- Sperm motility target via
membrane potential and ion
regulation
Gustavo Blanco
University of Kansas
CatSper
- Sperm motility target via
voltage-gated ion channels
Polina Lishko
UC Berkeley
Spermiogenesis
TSSK 1/2
- Spermiogenesis target via
haploinsufficiency
Pablo Visconti
UMASS Amherst
Gunda Georg
University of Minnesota
RAR alpha
- Spermatogenesis target via
arrested pachytene
spermatocytes
Debra Wolgemuth
Columbia University
H2-Gamendazole
- Spermiogenesis target via
late-stage Sertoli cell
junctions
Joseph Tash
University of Kansas
Gunda Georg
University of Minnesota
HIPK4
- Impaired spermiogenesis
& sperm structural defects
Gary Flynn
Vibliome Therapeutics
James Chen
Stanford University
Thomas Livinghouse
Montana State University
CDK2
- Spermiogenesis target via
meiotic alterations
Vargheese
Chennathukuzhi
University of Kansas
BRDT
- Spermiogenesis target via
chromatin structure
Jun Qi
Dana Farber
Cancer Institute
Possible / Undefined Targets
